Historical Press Releases

2013

Soligenix Receives IND Clearance from FDA to Initiate Program Evaluating OrbeShield™ as a Therapy for Gastrointestinal Acute Radiation Syndrome

Princeton, NJ – January 4, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that the Food and Drug Administration...

BARDA Invites Soligenix to Submit Contract Proposal for Development of OrbeShield™ in GI ARS

Princeton, NJ – January 7, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that pursuant to review of the Company’

FDA Grants Soligenix Fast Track Designation for OrbeShield™ for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)

Princeton, NJ – January 29, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that its OrbeShield™ (oral...

Soligenix Announces Formation of Oral Mucositis Medical Advisory Board

Princeton, NJ – February 4, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development-stage biopharmaceutical company, announced today the formation of a Medical Advisory...

Soligenix to Present at 15th Annual BIO CEO & Investor Conference

Princeton, NJ – February 8, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that its President and Chief...

Show 5102550100 per page